Overview GLP3-R is the catalog designation for retatrutide (LY3437943), a synthetic peptide characterized in the peer-reviewed literature as a single-molecule agonist at three receptors: GIP, GLP-1, and glucagon.[1] Coskun and colleagues published the discovery-to-proof-of-concept characterization in Cell Metabolism, and Urva et al. reported the first multiple-ascending-dose clinical pharmacology study in The Lancet.[1][2] What distinguishes this compound within the incretin literature is the th

How does GLP3-R work? What is its mechanism of action?

Reported Mechanism 1. Triple Receptor Engagement Retatrutide is described as engaging three class-B G-protein-coupled receptors with a single peptide sequence: the GIP receptor, the GLP-1 receptor, and the glucagon receptor.[1] This distinguishes it from dual GIP/GLP-1 agonism and from GLP-1-selective agonism, and it is the structural feature that defines the compound's research role.[8] 2. Incretin-Axis Signalling GLP-1 and GIP receptor agonism act on the incretin axis, where insulinotropic act

What are the research applications of GLP3-R?

Research Applications Published literature (all studies used the pharmaceutical formulation), organised by mechanism: Receptor pharmacology — Coskun et al. reported the discovery-to-proof-of-concept work defining triple GIP/GLP-1/glucagon agonism.[1] Clinical pharmacology — phase 1b and phase 2 trials of the pharmaceutical formulation are listed under References.[2][3][4][5] Gastric-emptying pharmacodynamics — Urva et al. reported effects on gastric emptying.[6] Comparative incretin pharmacology

What does the research summary say about GLP3-R?

Research Summary Foundational Studies StudyTypeSubject of ReportRef Coskun et al. (2022)Discovery / proof of conceptCharacterization of LY3437943 as a triple glucagon, GIP, and GLP-1 receptor agonist[1] Urva et al. (2022)Phase 1b multiple-ascending-dose trialClinical pharmacology[2] Jastreboff et al. (2023)Phase 2Triple-hormone-receptor agonist evaluated in a phase 2 trial[3] Rosenstock et al. (2023)Phase 2Placebo- and active-controlled parallel-group trial[4] Sanyal et al. (2024)Phase 2a (MASLD

How should GLP3-R be stored?

Store lyophilized at -20°C for long-term storage, or 2-8°C short-term. Keep tightly sealed, protected from light and moisture.

GLP3-R: Research Applications

From $69.30 · Lot COAs published for 4 of 4 sizes · Free BAC water + free U.S. shipping · Same-day dispatch before 2 PM ET · FOR RESEARCH USE ONLY

Buy GLP3-R Peptide - all sizes

10 PubMed CitationsExpert ReviewedLast Reviewed: July 2026

Research Applications

Published literature (all studies used the pharmaceutical formulation), organised by mechanism:

Receptor pharmacology — Coskun et al. reported the discovery-to-proof-of-concept work defining triple GIP/GLP-1/glucagon agonism.[1]
Clinical pharmacology — phase 1b and phase 2 trials of the pharmaceutical formulation are listed under References.[2][3][4][5]
Gastric-emptying pharmacodynamics — Urva et al. reported effects on gastric emptying.[6]
Comparative incretin pharmacology — the compound serves as the triple-agonist arm in comparisons against dual and selective agonists.[7][8]

Editorial Research Note

“Research Summary Foundational Studies StudyTypeSubject of ReportRef Coskun et al.”

Pure U.S. Peptides Research Standards TeamInternal editorial group summarising published peptide research for an audience of qualified independent investigators.

References

Related research

Cagriniltide — Research applications GLP2-T — Research applications

Browse all research guides in the Peptide Research Library →

Want the complete research review?

Buy GLP3-R Peptide - all sizes→

FOR RESEARCH USE ONLY

This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.